Multi‐omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited‐stage small cell lung cancer to definitive chemoradiotherapy

Documenti analoghi

• Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non‐small‐cell lung cancer
  di: Yu Wang, et al.
  Pubblicazione: (2024)
• Machine learning and radiomics for predicting efficacy of programmed cell death protein 1 inhibitor for small cell lung cancer: A multicenter cohort study
  di: Pulin Li, et al.
  Pubblicazione: (2024)
• Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer
  di: Ailing Cao, et al.
  Pubblicazione: (2026)
• Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
  di: Weilong Zhang, et al.
  Pubblicazione: (2025)
• Multi‐omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer
  di: Ying Cheng, et al.
  Pubblicazione: (2024)